1. Home
  2. ATXG vs BIAF Comparison

ATXG vs BIAF Comparison

Compare ATXG & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Addentax Group Corp.

ATXG

Addentax Group Corp.

SELL

Current Price

$2.39

Market Cap

4.5M

ML Signal

SELL

Logo bioAffinity Technologies Inc.

BIAF

bioAffinity Technologies Inc.

SELL

Current Price

$1.75

Market Cap

3.9M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
ATXG
BIAF
Founded
2014
2014
Country
China
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.5M
3.9M
IPO Year
2015
2022

Fundamental Metrics

Financial Performance
Metric
ATXG
BIAF
Price
$2.39
$1.75
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
31.9K
★ 76.4K
Earning Date
12-01-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $7,900,000.00
Revenue This Year
N/A
$18.58
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 14.49
52 Week Low
$0.28
$0.37
52 Week High
$9.56
$21.52

Technical Indicators

Market Signals
Indicator
ATXG
BIAF
Relative Strength Index (RSI) 37.69 30.80
Support Level $1.93 $1.56
Resistance Level $3.97 $1.74
Average True Range (ATR) 0.36 0.27
MACD -0.00 0.03
Stochastic Oscillator 33.80 1.97

Price Performance

Historical Comparison
ATXG
BIAF

About ATXG Addentax Group Corp.

Addentax Group Corp is an investment holding company. The company through its operating subsidiaries functions in the following segments; Garment manufacturing; Logistics services and Consulting. It generates maximum revenue from the Logistics services segment which provides logistics services including storage, transportation, warehousing, handling, packaging, and order processing. It also provides customs declaration and tax clearance services to its customers who export goods overseas. Geographically, the company derives all of its revenue from China.

About BIAF bioAffinity Technologies Inc.

bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.

Share on Social Networks: